Otras espondiloartritis

  1. García García, V. 1
  2. Briones Figueroa, A. 1
  3. Valero Expósito, M. 1
  4. Blanco Cáceres, B.A. 1
  5. Bachiller Corral, J. 1
  1. 1 Servicio de Reumatología, Hospital Universitario Ramón y Cajal, Madrid, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2021

Serie: 13

Número: 29

Páxinas: 1635-1648

Tipo: Artigo

DOI: 10.1016/J.MED.2021.03.021 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Obxectivos de Desenvolvemento Sustentable

Resumo

Spondyloarthritis (SpA) conditions include axial and peripheral SpA. However, there are others such as reactive arthritis (ReA), arthritis conditions linked to inflammatory bowel disease (IBD) or synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome; these are common in rheumatology consultations, although less frequent than cases of ankylosing spondylitis (AS) or psoriatic arthritis (PsA). These conditions can present with either axial or peripheral signs and symptoms, and with extra-articular such as, ophthalmological or cutaneous manifestations. The most frequent form of ReA presentation is oligoarthritis of the lower limbs, with axial involvement being more infrequent. In IBD-associated arthropathy, symptoms can appear at any level. Axial symptoms predominate in SAPHO syndrome. Diagnosis is principally based on the symptoms and radiological findings, without any unanimous diagnostic criteria. For joint symptoms, the first line of treatment is non-steroidal anti-inflammatory drugs, although with restrictions in the case of IBD-associated arthropathy, with the use of systemic or local corticoids also being possible (systemic corticoids should not be used if there is axial involvement). If the first line of treatment is not successful, the treatment indicated is disease-modifying drugs such as sulfasalazine and, if necessary, biological drugs (especially anti-tumour necrosis factor —TNF— therapy); these have been used in these pathologies with varied responses.

Referencias bibliográficas

  • Stolwijk C, Boonen A, van Tubergen A, Reveille JD. Epidemiology of spondyloarthritis. Rheum Dis Clin North Am. 2012;38(3):441-76.
  • Hannu T. Reactive arthritis. Best Pract Res Clin Rheumatol. 2011;25(3):347-57.
  • Schmitt SK. Reactive arthritis. Infect Dis Clin North Am. 2017; 31(2):265-77.
  • Selmi C, Gershwin ME. Diagnosis and classification of reactive arthritis. Autoimmun Rev. 2014;13(4-5):546-9.
  • Gerard HC, Stanich JA, Whittum Hudson JA, Schumacher HR, Carter JD, Hudson AP. Patients with Chlamydia associated arthritis have ocular (trachoma), not genital, serovars of C. trachomatis in synovial tissue. Microb Pathog. 2010;48(2):62-8.
  • Chaurasia S, Shasany AK, Aggarwal A, Misra R. Recombinant Salmonella typhimurium outer membrane protein A is recognized by synovial fluid CD8 cells and stimulates synovial fluid mononuclear cells to produce interleukin (IL)-17/IL-23 in patients with reactive arthritis and undifferentiated spondyloarthropathy. Clin Exp Immunol. 2016;185(2):210-8.
  • Lucchino B, Spinelli FR, Perricone C, Valesini G, Di Franco M. Reactive arthritis: current treatment challenges and future perspectives. Clin Exp Rheumatol. 2019;37:1065-76.
  • Muñoz Fernández S. Artritis reactiva. En: Manual SER de enfermedades reumáticas. 6ª ed. Madrid: Sociedad Española de Reumatología. Elsevier; 2014. p. 285-8.
  • Leirisalo Repo M. Reactive arthritis. Scand J Rheumatol. 2005;34(4):251-9.
  • Carter JD, Espinoza LR, Inman RD, Sneed KB, Ricca LR, Vasey FB, Combination antibiotics as a treatment for chronic Chlamydia induced reactive arthritis: a double blind, placebo controlled, prospective trial. Arthritis Rheum. 2010;62(5):1298-307.
  • Hannu T, Inman R, Granfors K, Leirisalo Repo M. Reactive arthritis or post infectious arthritis? Best Pract Res Clin Rheumatol. 2006;20(3):419-33.
  • Jendro MC, Raum E, Schnarr S, Köhler L, Zeidler H, Kuipers JG, Cytokine profile in serum and synovial fluid of arthritis patients with Chlamydia trachomatis infection. Rheumatol Int. 2005;25(1):37-41.
  • Sieper J, Rudwaleit M, Braun J, van der Heijde D. Diagnosing reactive arthritis: role of clinical setting in the value of serologic and microbiologic assays. Arthritis Rheum. 2002;46(2):319-27.
  • Sociedad Española de Reumatología. Grupo de trabajo ESPOGUIA. Guía de Práctica Clínica sobre el Manejo de los Pacientes con Espondiloartritis. Madrid: Sociedad Española de Reumatología; 2009.
  • Braun J, Kingsley G, van der Heijde D, Sieper J. On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999. J Rheumatol. 2000;27(9):2185-92.
  • Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25-31.
  • Fox R, Calin A, Gerber RC, Gibson D. The chronicity of symptoms and disability in Reiter’s syndrome. An analysis of 131 consecutive patients. Ann Intern Med. 1979;91(2):190-3.
  • Barber CE, Kim J, Inman RD, Esdaile JM, James MT. Antibiotics for treatment of reactive arthritis: a systematic review and metaanalysis. J Rheumatol. 2013;40(6):916-28.
  • Clegg DO, Reda DJ, Weisman MH, Cush JJ, Vasey FB, Schumacher HR, Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter’s syndrome). A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39(12):2021-7.
  • Meyer A, Chatelus E, Wendling D, Berthelot JM, Dernis E, Houvenagel E, Safety and efficacy of anti tumor necrosis factor α therapy in ten patients with recent onset refractory reactive arthritis. Arthritis Rheum. 2011;63(5):1274-80.
  • Brakenhoff LK, van der Heijde DM, Hommes DW, Huizinga TW, Fidder HH. The joint gut axis in inflammatory bowel diseases. J Crohns Colitis. 2010 Sep;4(3):257-68.
  • Peluso R, Di Minno M, Iervolino S, Manguso F, Tramontano G, Ambrosino P, Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Dev Immunol. 2013;2013:631408.
  • Arvikar SL, Fisher MC. Inflammatory bowel disease associated arthropathy. Curr Rev Musculoskelet Med. 2011;4(3):123-31.
  • Gracey E, Vereecke L, McGovern D, Fröhling M, Schett G, Danese S, Revisiting the gut joint axis: links between gut inflammation and spondyloarthritis. Nat Rev Rheumatol. 2020;16:415-33.
  • Fragoulis G, Liava C, Daoussis D, Akriviadis E, Garyfallos A, Dimitroulas T. Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment. World J Gastroenterol. 2019;25(18):2162-76.
  • Smale S, Natt RS, Orchard TR, Russell AA, Bjarnason I. Inflammatory bowel disease and spondyloarthropathy. Arthritis Rheum. 2001;44: 2728-36.
  • Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42:387-91.
  • Sanz J, Juanola X, Seoane Matoc D, Montorod M, Gomollón F, Grupo de Trabajo del proyecto PIIASER. Criterios de cribado de enfermedad inflamatoria intestinal y espondiloartritis para derivación de pacientes entre Reumatología y Gastroenterología. Reumatol Clin. 2018;14(2):68-74.
  • Wordsworth P. Arthritis and inflammatory bowel disease. Curr Rheumatol Rep. 2000;2(2):87-8.
  • Guardiola J, Lobatón T, Cerrillo E, Ferreiro Iglesias R, Gisbert J, Domènech E, et al. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la utilidad de la determinación de calprotectina fecal en la enfermedad inflamatoria intestinal. Gastroenterol Hepatol. 2018;41(8):514-29.
  • Gonzáñez Lama Y, Sanz J, Bastida G, Campos J, Ferrerio R, Joven B, Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el tratamiento de pacientes con enfermedad inflamatoria intestinal asociada a espondiloartritis. Gastroenterol Hepatol. 2020;43(5): 273-83.
  • Van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978-91.
  • Gratacós J, Díaz del Campo P, Fernández Carballidoc C, Juanola X, Linares L, De Miguel E, Recomendaciones de la So-ciedad Española de Reumatología sobre el uso de terapias biológicas en espondiloartritis axial. Reumatol Clin. 2018;14(6):320-33.
  • Carneiro S, Sampaio Barros P. SAPHO syndrome. Rheum Dis Clin North Am. 2013;39(2):401-18.
  • Rukavina I. SAPHO syndrome: a review. J Child Orthop. 2015;9(1): 19-27.
  • Cianci F, Zoli A, Gremese F, Ferraccioli G. Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment. Clin Rheumatol. 2017;36:2151-58.
  • Depasquale R, Kumar N, Lalam R, Tins B, Tyrrell P, Singh J, SAPHO: what radiologists should know. Clin Radiol. 2012;67(3): 195-206.
  • Kahn M, Khan M. The SAPHO syndrome. Baillieres Clin Rheumatol. 1994;8(2):333-62.
  • Daoussis D, Konstantopoulou G, Kraniotis P, Sakkas L, Liossis S. Biologics in SAPHO syndrome: A systematic review. Semin Ar-thritis Rheum. 2019;48(4):618-25.
Fonte de datos: Dialnet